Clinical Trials on Meningitis in New Zealand

Total 62 results

Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Meningitis | Neisseria Meningitidis | Meningococcemia

United States
Pfizer

Completed

An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi

Completed

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
National Institute of Allergy and Infectious Diseases...

Completed

Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis

Cryptococcal Meningitis

United States, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
Pfizer

Completed

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
InterMune

Completed

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States, Peru
All India Institute of Medical Sciences, New Delhi

Recruiting

Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes

Tuberculous Meningitis | Tuberculous Arachnoiditis

India
National Institute of Allergy and Infectious Diseases...
Washington University School of Medicine

Completed

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dexamethasone in Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States, Puerto Rico
Pfizer

Completed

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States, Canada
GlaxoSmithKline

Completed

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

Meningitis, Meningococcal

Australia, Germany
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Pfizer

Completed

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

HIV Infections | Meningitis, Cryptococcal

United States
National Institute of Allergy and Infectious Diseases...
Schering-Plough

Completed

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

HIV Infections | Meningitis, Cryptococcal

United States
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Meningococcal Disease | Meningococcal Meningitis

United States, Canada
Pfizer

Completed

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States, Canada
Novartis
Novartis Vaccines

Completed

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Meningococcal Meningitis

United States, Italy
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal

United States, Australia, Argentina, Canada
GlaxoSmithKline

Active, not recruiting

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Meningitis, Meningococcal

Germany, United States
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
University of Adelaide

Completed

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults (AMEND)

Meningococcal Infections | Neisseria Infection | Neisseria Meningitis Sepsis

Australia
Liposome

Completed

Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

HIV Infections | Meningitis, Cryptococcal

United States
NICHD Neonatal Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Early-Onset Sepsis an NICHD/CDC Surveillance Study (EOSII)

Infant, Newborn, Diseases | Early Onset Neonatal Sepsis | Early-Onset Meningitis

United States
Pfizer
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

HIV Infections | Meningitis, Cryptococcal

United States
Pacira Pharmaceuticals, Inc

Completed

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

Meningeal Neoplasms

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Chile
National Institute of Allergy and Infectious Diseases...
International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Completed

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

HIV Infections | Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Puerto Rico
Sanofi

Completed

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States
Alkermes, Inc.

Completed

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

HIV Infections | Meningitis, Cryptococcal

United States
Pfizer

Completed

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

HIV Infections | Meningitis, Cryptococcal

United States, Canada
Sanofi

Completed

A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

Meningitis | Meningococcal Infection

India
Papua New Guinea Institute of Medical Research
The University of Western Australia

Completed

Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea

Pneumonia | Meningitis | Otitis Media

Papua New Guinea
St. Luke's-Roosevelt Hospital Center

Terminated

Does Static Ultrasound-Preview Reduce the Incidence of Difficult Lumbar Puncture?

Headache | Meningitis | Subarachnoid Hemorrhage

United States
Stony Brook University
Karius, Inc.

Completed

Next Generation Sequencing Detection of Lyme Disease

Lyme Disease | Lyme Arthritis | Pediatric Infectious Disease | Erythema Migrans | Lyme Carditis | Lyme Disease Meningitis

United States
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Meningitis | Meningococcemia

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
Papua New Guinea Institute of Medical Research
The University of Western Australia

Unknown

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children (PCV1103)

Pneumonia | Sepsis | Meningitis | Otitis Media | Bacteraemia

Papua New Guinea
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

Meningitis | Meningococcal Infection

United States

Clinical Trials on Meningitis in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations